#By Prof Vanessa Smith #NVC 🟢Only Raynauds (+) 🔴NVC (-) Antihody (-) ⚠️1.8% chance to progress to SSc over 20 yrs 🟢Raynauds+Antibody+ NVC (+) 💥💥 Transition to Ssc 65.9% in 5 yrs / 79.5% in 15 yrs!! Scleroderma India World Scleroderma Foundation @scleroderma

Idiopathic inflammatory myopathies (IIM), a rare condition causing severe disabilities, can lead to Interstitial Lung Disease (ILD), an even-more devastating manifestation. Our team found that PET imaging of FAPi-uptake is a biomarker for ILD. 👉 tinyurl.com/y4nsfc3b

A picture tells more than a thousand words... thank you all for sharing that moment with me, and for making the @EULAR 2024 Congress an unforgettable event!!

📝Just published: guideline scope for the new BSR guideline for systemic autoimmune rheumatic disease-related interstitial lung disease. Learn why our members proposed this guideline and access the scope here: bit.ly/45r6DBV ILD IPF Doc: Nazia Chaudhuri Jennifer Hannah Mia Rodziewicz

Very happy to see Prof. Maurizio Cutolo! His presentation on intermediate pattern is quite interesting! "We want delete the late pattern in the future" Congratulation for 20 years of Capillaroscopy course! #EULAR2024 #WorldSclerodermaday #Scleroderma pubmed.ncbi.nlm.nih.gov/38287630/

#EULAR24 was excellent!

#WorldArthritisDay is held annually on 12 October. #WAD aims to help raise awareness of the existence and impact of rheumatic and musculoskeletal diseases, often referred to as #RMDs. Care about arthritis and RMDs!

A new player in AIRD ThA age associated T helper cells Displaying both Cytotoxic & APC functions Correlation with disease activity in RA and SLE More research is needed to better characterize function but could be a promising therapeutic target Dr. John Cush #APLAR25

Great talk by Dr. Andrea Low on CTD-ILD 💡 She highlighted a personalized approach to treatment — balancing ILD extent, risk of progression, biology, extrapulmonary features & adverse effects. #APLAR25 #Rheumatology #ILD

Dr. Alberta Hoi graphically presents the difference bet acute confusional states & chronic cognitive changes in #lupus patients presenting with NP symptoms. NPSLE continues to pose a diagnostic challenge bec pts may present with more than one syndrome complex Dr. John Cush #APLAR25

Prof. Masataka Kuwana 🇯🇵 highlights: PH with ILD in SARDs = severe complication with high morbidity & mortality 🚨. 🌸 Inhaled treprostinil offers hope for better outcomes 💊 Sildenafil safe, well-tolerated, option if treprostinil unavailable #APLAR25 #Rheumatology #PH #ILD

✅ Strikingly ~40% of all active investigational #trials in #SLE assess a type of cellular therapy, of which anti-CD19 #CART represents the highest proportion, among various other targets and and targeting constructs ⬇️ #APLAR25

✅ What are the main goals of #Rheumatology specialists when treating systemic #Lupus in 2025? Our aim is mostly to attain - and then maintain - #remission, with many other favorable outcomes associated with this state👌the longer the better 🙏 #APLAR25

#APLAR 2025 Fukuoka Japan was tremendous. Thank you Prof Tanaka and #JCR!

#APLAR25

RA Awareness Week starts tomorrow! 💜 This year we’re highlighting the importance of recognising the symptoms of Rheumatoid Arthritis and why early diagnosis matters. RA is an autoimmune disease that doesn’t just affect joints – it can impact the heart, lungs, eyes and more.